Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Desablens

Showing results (91-100 of 101) with videos related to

Pageof 11
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2000
Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues MyeloblastiquesJ L Harousseau, B Witz, B Lioure, et al.
American Journal of Clinical Pathology|November 5, 1998
Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Ouest Est d'étude des Leucénies et Autres Maladies du Sang (GOELAMS)S Camilleri-Broët, A Martin, A Moreau, et al.
Bone Marrow Transplantation|June 12, 2002
Front-line high-dose therapy with autologous stem cell transplantation for high risk Hodgkin's disease: comparison with combined-modality therapyS Vigouroux, N Milpied, J M Andrieu, et al.
Blood|November 5, 1997
Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM)J L Harousseau, J Y Cahn, B Pignon, et al.
Blood|May 16, 1998
A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM)F Witz, A Sadoun, M C Perrin, et al.
British Journal of Haematology|August 1, 1996
Treatment of acute myelogenous leukaemia in patients aged 50-65: idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course. The Goelam GroupB Pignon, F Witz, B Desablens, et al.
Bone Marrow Transplantation|May 1, 1996
The treatment of chronic myelogenous leukemia by interferon and cytosine-arabinoside: rational and design of the French trials. French CML Study GroupF Guilhot, A Guerci, D Fiere, et al.
British Journal of Haematology|September 12, 1998
Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized studyE Wattel, E Solary, B Hecquet, et al.
Blood|August 10, 1999
A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL GroupP Fenaux, C Chastang, S Chevret, et al.
Advances in Experimental Medicine and Biology|September 29, 1999
Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMSE Wattel, E Solary, B Hecquet, et al.
Pageof 11

Showing results (91-100 of 101) with videos related to

Sort By:
Pageof 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2000
Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues MyeloblastiquesJ L Harousseau, B Witz, B Lioure, et al.
American Journal of Clinical Pathology|November 5, 1998
Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Ouest Est d'étude des Leucénies et Autres Maladies du Sang (GOELAMS)S Camilleri-Broët, A Martin, A Moreau, et al.
Bone Marrow Transplantation|June 12, 2002
Front-line high-dose therapy with autologous stem cell transplantation for high risk Hodgkin's disease: comparison with combined-modality therapyS Vigouroux, N Milpied, J M Andrieu, et al.
Blood|November 5, 1997
Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM)J L Harousseau, J Y Cahn, B Pignon, et al.
Blood|May 16, 1998
A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM)F Witz, A Sadoun, M C Perrin, et al.
British Journal of Haematology|August 1, 1996
Treatment of acute myelogenous leukaemia in patients aged 50-65: idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course. The Goelam GroupB Pignon, F Witz, B Desablens, et al.
Bone Marrow Transplantation|May 1, 1996
The treatment of chronic myelogenous leukemia by interferon and cytosine-arabinoside: rational and design of the French trials. French CML Study GroupF Guilhot, A Guerci, D Fiere, et al.
British Journal of Haematology|September 12, 1998
Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized studyE Wattel, E Solary, B Hecquet, et al.
Blood|August 10, 1999
A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL GroupP Fenaux, C Chastang, S Chevret, et al.
Advances in Experimental Medicine and Biology|September 29, 1999
Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMSE Wattel, E Solary, B Hecquet, et al.
Pageof 11